Chandra Bhagat Pharm
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Chandra Bhagat Pharma's board approved issuing up to 66 lakh convertible warrants at ₹44 each on a preferential basis, raising as much as ₹29.04 crore from nine investors, mainly the promoter family and two non-promoters. Each warrant converts into one equity share within 18 months of allotment, with 25% payable upfront and the balance at conversion. The board also approved raising the authorised share capital to ₹15 crore from ₹8.5 crore. The issue is subject to shareholder approval at the annual general meeting on September 1.
Powered by Tijori
Chandra Bhagat Pharma's board approved issuing up to 66 lakh convertible warrants at ₹44 each on a preferential basis, raising as much as ₹29.04 crore from nine investors, mainly the promoter family and two non-promoters. Each warrant converts into one equity share within 18 months of allotment, with 25% payable upfront and the balance at conversion. The board also approved raising the authorised share capital to ₹15 crore from ₹8.5 crore. The issue is subject to shareholder approval at the annual general meeting on September 1.
Powered by Tijori
July 30 (Reuters) - Chandra Bhagat Pharma Ltd CHAB.BO:
CHANDRA BHAGAT PHARMA LTD - TO CONSIDER A PROPOSAL OF FUND RAISING
CHANDRA BHAGAT PHARMA - TO CONSIDER FUND RAISING VIA PREFERENTIAL ALLOTMENT OF EQUITY OR WARRANTS
Source text: ID:nBSE6dygp8
Further company coverage: CHAB.BO
(([email protected];))
July 30 (Reuters) - Chandra Bhagat Pharma Ltd CHAB.BO:
CHANDRA BHAGAT PHARMA LTD - TO CONSIDER A PROPOSAL OF FUND RAISING
CHANDRA BHAGAT PHARMA - TO CONSIDER FUND RAISING VIA PREFERENTIAL ALLOTMENT OF EQUITY OR WARRANTS
Source text: ID:nBSE6dygp8
Further company coverage: CHAB.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Chandra Bhagat Pharm do?
Chandra Bhagat Pharma Pvt Ltd specializes in providing a range of life-saving medicines in India through its diverse portfolio, including cardiovascular drugs, antibiotics, and neurology drugs.
Who are the competitors of Chandra Bhagat Pharm?
Chandra Bhagat Pharm major competitors are Welcure Drugs&Pharma, Gujarat Terce Labs., Deccan Health Care, Medicamen Organics, Panjon, Walpar Nutritions, Medistep Healthcare. Market Cap of Chandra Bhagat Pharm is ₹33 Crs. While the median market cap of its peers are ₹32 Crs.
Is Chandra Bhagat Pharm financially stable compared to its competitors?
Chandra Bhagat Pharm seems to be less financially stable compared to its competitors. Altman Z score of Chandra Bhagat Pharm is 2.29 and is ranked 5 out of its 8 competitors.
Does Chandra Bhagat Pharm pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Chandra Bhagat Pharm latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Chandra Bhagat Pharm allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Chandra Bhagat Pharm balance sheet?
Balance sheet of Chandra Bhagat Pharm is moderately strong.
Is the profitablity of Chandra Bhagat Pharm improving?
The profit is oscillating. The profit of Chandra Bhagat Pharm is ₹3.05 Crs for Mar 2026, ₹0.86 Crs for Mar 2025 and ₹1.53 Crs for Mar 2024
Is the debt of Chandra Bhagat Pharm increasing or decreasing?
The net debt of Chandra Bhagat Pharm is decreasing. Latest net debt of Chandra Bhagat Pharm is ₹10.31 Crs as of Mar-26. This is less than Mar-25 when it was ₹19.75 Crs.
Is Chandra Bhagat Pharm stock expensive?
Chandra Bhagat Pharm is not expensive. Latest PE of Chandra Bhagat Pharm is 10.75, while 3 year average PE is 128. Also latest EV/EBITDA of Chandra Bhagat Pharm is 19.39 while 3yr average is 32.0.
Has the share price of Chandra Bhagat Pharm grown faster than its competition?
Chandra Bhagat Pharm has given better returns compared to its competitors. Chandra Bhagat Pharm has grown at ~-21.89% over the last 2yrs while peers have grown at a median rate of -31.0%
Is the promoter bullish about Chandra Bhagat Pharm?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 73.02% and last quarter promoter holding is 72.19%.
Are mutual funds buying/selling Chandra Bhagat Pharm?
There is Insufficient data to gauge this.